Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX), raises PT from $10 to $13.

Canaccord analyst says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE